Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab) in combination with other therapies…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma…
